source
- Cytokinetics' HCM drug shows positive trial results, potentially doubling market after Bristol Myers' setbackCytokinetics announced that its oral therapy for hypertrophic cardiomyopathy (HCM) achieved positive results in a pivotal trial targeting a different form of the disease. The data suggest the drug…
- Expert discusses how clinicians choose between FOLFIRINOX and newly approved NALIRIFOX for metastatic pancreatic cancerDr. Deirdre J. Cohen, director of GI Oncology at Mount Sinai, provides commentary on how doctors decide on frontline chemotherapy for metastatic pancreatic cancer. She notes that, as of 2026, ther…